No difference in retinal fluorescence after oral curcumin intake in amyloid proven AD cases compared to controls

Haan, Jurre den; Ruyter, Frederique J. Hart de; Lochocki, Benjamin; Kroon, Maurice A.G.M.; Kemper, E. Marleen; Teunissen, Charlotte E.; Berckel, Bart van; Scheltens, Philip; Hoozemans, Jeroen J.M.; Kreeke, Aleid van de; Verbraak, Frank D.; Boer, Johannes F. de; Bouwman, Femke H.

doi:10.1101/2021.10.07.21264420

Cited by 1 publication

(2 citation statements)

References 35 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methodological differences in curcumin protocols and quantification may explain the varied findings (Table 1). Ngolab et al (29) theorized that the higher RAC they found compared with Koronyo et al may have been due to higher curcumin dosing over a shorter period, whereas results from den Haan et al (31) suggest that curcumin uptake may vary. In addition, the retina's inherent autofluorescence may mask the curcumin signal.…”

Section: Curcumin Fluorescencementioning

confidence: 91%

“…Although the abovementioned studies strongly suggest the presence of retinal Ab in AD and associations between retinal Ab and cognition and/or AD pathology in the brain, den Haan et al (31) found no differences in retinal fluorescent signals between patients with biomarker positive AD and NCs using 3 formulations of oral curcumin. In participants who received the standard formulation (Longvida, Verdure Sciences, Noblesville, IN), quantitative assessment revealed no difference in hyperfluorescence between biomarkerpositive AD participants and NCs.…”

Section: Curcumin Fluorescencementioning

confidence: 98%

See 1 more Smart Citation

Imaging Amyloid and Tau in the Retina: Current Research and Future Directions

Tang¹,

Blazes²,

Lee³

2023

Journal of Neuro-Ophthalmology

View full text Add to dashboard Cite

Background: The retina is a key focus in the search for biomarkers of Alzheimer's disease (AD) because of its accessibility and shared development with the brain. The pathological hallmarks of AD, amyloid beta (Ab), and hyperphosphorylated tau (pTau) have been identified in the retina, although histopathologic findings have been mixed. Several imaging-based approaches have been developed to detect retinal AD pathology in vivo. Here, we review the research related to imaging AD-related pathology in the retina and implications for future biomarker research. Evidence Acquisition: Electronic searches of published literature were conducted using PubMed and Google Scholar.Results: Curcumin fluorescence and hyperspectral imaging are both promising methods for detecting retinal Ab, although both require validation in larger cohorts. Challenges remain in distinguishing curcumin-labeled Ab from background fluorescence and standardization of dosing and quantification methods. Hyperspectral imaging is limited by confounding signals from other retinal features and variability in reflectance spectra between individuals. To date, evidence of tau aggregation in the retina is limited to histopathologic studies. New avenues of research are on the horizon, including near-infrared fluorescence imaging, novel Ab labeling techniques, and small molecule retinal tau tracers. Artificial intelligence (AI) approaches, including machine learning models and deep learning-based image analysis, are active areas of investigation. Conclusions: Although the histopathological evidence seems promising, methods for imaging retinal Ab require further validation, and in vivo imaging of retinal tau remains elusive. AI approaches may hold the greatest promise for the discovery of a characteristic retinal imaging profile of AD. Elucidating the role of Ab and pTau in the retina will provide key insights into the complex processes involved in aging and in neurodegenerative disease.

show abstract

Section: Curcumin Fluorescencementioning

confidence: 91%

Section: Curcumin Fluorescencementioning

confidence: 98%